Clinical Cases  ·  Gastroenterology IV  ·  Biliary Tract
← Back to Gastroenterology IV
Gastroenterology

Biliary Tract

11 cases spanning cholangiocarcinoma targeted therapy, gallstone and choledocholithiasis management, sphincter of Oddi dysfunction, and post-transplant biliary complications — choose a case below to open its full multi-voice debate.

GastroenterologyBiliary Tract
FGFR2-Positive Cholangiocarcinoma: Pemigatinib Now or Chemotherapy First

A newly diagnosed FGFR2 fusion-positive cholangiocarcinoma, and whether real trial evidence for first-line targeted therapy is reachable before her insurer has had a chance to say no.

Case 0001
GastroenterologyBiliary Tract
IDH1-Mutant Cholangiocarcinoma After First-Line Failure: Ivosidenib or FOLFOX

Progression after first-line gemcitabine-cisplatin-durvalumab in IDH1-mutant cholangiocarcinoma, and whether a better-tolerated targeted drug or a survival-proven chemotherapy regimen goes first.

Case 0002
GastroenterologyBiliary Tract
Biomarker-Negative Cholangiocarcinoma: Durvalumab or Pembrolizumab Alongside Chemotherapy

A newly diagnosed unresectable cholangiocarcinoma with no actionable mutation, and two real, FDA-approved immunotherapy combinations with no head-to-head trial to choose between them.

Case 0003
GastroenterologyBiliary Tract
Acute Cholangitis After Source Control: How Long to Keep the Antibiotics Going

Acute cholangitis, cleared endoscopically and clinically improving by hospital day three — and whether the antibiotic course a procedure note actually documents, not a fixed number of days, should decide when to stop.

Case 0004
GastroenterologyBiliary Tract
Acute Cholangitis at 28 Weeks: Antibiotic Choice When the Patient Isn't the Only One at Risk

Acute cholangitis at 28 weeks, hours before ERCP achieves real source control — and choosing antibiotic coverage that protects both the mother's actual severity and the fetus at the same time.

Case 0005
GastroenterologyBiliary Tract
Cholesterol Gallstones in a Patient Who Can't Safely Go to the OR: Dissolving Them Instead

Symptomatic cholesterol gallstones in a patient anesthesia and cardiology both flag as prohibitive surgical risk, and whether oral dissolution therapy is a real alternative or just a slower version of the same eventual conversation.

Case 0006
GastroenterologyBiliary Tract
Starting Tirzepatide, Losing Weight Fast: Does She Need Gallstone Prophylaxis Too

A patient about to start high-dose tirzepatide, asking whether the gallstone-prophylaxis logic built for bariatric surgery actually applies to incretin-driven weight loss too.

Case 0007
GastroenterologyBiliary Tract
Biliary Dyskinesia at a Borderline HIDA Result: Trial of Therapy or Straight to Surgery

A young patient with a borderline gallbladder ejection fraction but pain reproduced during the scan itself, and whether a time-limited medical trial or proceeding straight to cholecystectomy better fits what the test actually showed.

Case 0008
GastroenterologyBiliary Tract
Recurrent Biliary Pain After Cholecystectomy: Sphincter of Oddi Dysfunction Without Rushing to Sphincterotomy

Recurrent biliary-type pain more than a year after cholecystectomy, with one real objective finding that places her outside the population a landmark negative trial actually studied.

Case 0009
GastroenterologyBiliary Tract
Acute Cholecystitis, Too High-Risk for the OR: Antibiotics Alone or a Drainage Tube

Acute calculous cholecystitis in an 84-year-old ruled unsafe for general anesthesia, and whether a time-limited antibiotics-alone trial or percutaneous drainage is the right first move.

Case 0010
GastroenterologyBiliary Tract
A Biliary Stricture After Transplant: Bridging With UDCA While Waiting for the Stent

A rising cholestatic picture from a mechanical anastomotic stricture, a three-week wait for the ERCP slot that actually fixes it, and whether starting a bridge therapy risks the fix being forgotten. ---

Case 0011
← Back to Gastroenterology IV